Science Spotlight: Clues from the clinic for neoantigen prioritization

Molecular characterization of patient tumors identified RNA splicing aberrations that produce public neoantigens, and a clonal evolution-informed strategy for selecting personalized neoantigens. The findings, each described in a Nature paper, could inform neoantigen vaccine and cell therapy design.

In the first Nature paper, collaborators from University of California San Francisco and  Memorial Sloan Kettering Cancer Center characterized a class of neoantigens that are generated as a result of dysregulated splicing factor expression in multiple individuals and tumor types, and could thus serve as targets for off-the-shelf immunotherapies...